EP Patent

EP3804811A1 — Treatment of mood and anxiety disorders

Assigned to Icahn School of Medicine at Mount Sinai · Expires 2021-04-14 · 5y expired

What this patent protects

The present disclosure provides compositions and formulations containing neuropeptide Y and methods of their use for the treatment of mood and anxiety disorders.

USPTO Abstract

The present disclosure provides compositions and formulations containing neuropeptide Y and methods of their use for the treatment of mood and anxiety disorders.

Drugs covered by this patent

esketamine-hydrochloride (ESKETAMINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP3804811A1
Jurisdiction: EP
Classification: —
Expires: 2021-04-14
Drug substance claim: No
Drug product claim: No
Assignee: Icahn School of Medicine at Mount Sinai
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.